Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme CorpfiledCriticalGenzyme Corp
Priority to ARP120103340priorityCriticalpatent/AR087833A1/en
Publication of AR087833A1publicationCriticalpatent/AR087833A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente se refiere a anticuerpos monoclonales humanizados que comprenden las CDR de BMA031 anticuerpo murino, que se unen al complejo ab-TCR.CD3 y poseen propiedades biológicas mejoradas. Reivindicación 1: Un anticuerpo monoclonal humanizado específico para el complejo humano abTCR/CD3 que comprende una cadena pesada de región variable que comprende los CDRs establecidos en SEQ ID Nº 7, 12 ó 13 y una estructura humana IGH3-23 establecida en SEQ ID Nº 17, donde la posición 6 de la estructura es un residuo donante.This refers to humanized monoclonal antibodies that comprise the murine antibody BMA031 CDRs, which bind to the ab-TCR.CD3 complex and possess improved biological properties. Claim 1: A humanized monoclonal antibody specific for the human abTCR / CD3 complex comprising a heavy region variable chain comprising the CDRs established in SEQ ID No. 7, 12 or 13 and a human IGH3-23 structure established in SEQ ID No. 17 , where position 6 of the structure is a donor residue.
ANTIGENIC CHIMERICAL RECEPTOR (CAR) THAT INCLUDES A DOMAIN OF BINDING TO ANTIGENS, WHICH SELECTIVELY JOINES THE CONSTANT REGION OF THE TCR BETA 1 (TRBC1) OR TRBC2 OF T CELLS
monoclonal antibodies, use of anti-pd1, anti-pd-1 and anti-ctla-4 antibodies in immunotherapy and cancer treatment, as well as kits and individual selection process for treatment with anti-pd-1 antibody